Sponsored Links
| Abbott's HUMIRA® (Adalimumab) Meets Primary Endpoints In Phase III Ulcerative Colitis Study |
 |
 |
 |
| Medical News - Crohn's | |||
|
Abbott's (NYSE: ABT) HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis. Results were presented at the Digestive Disease Week (DDW) scientific conference in Chicago... Read more: Crohn's / IBD News From Medical News Today
|